Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
Lawrence G LumZaid Al-KadhimiAbhinav DeolVidya KondadasulaDana SchalkElyse TomashewskiPatricia SteeleKristie FieldsMelissa GirouxQin LiuLawrence FlahertyMichael SimonArchana ThakurPublished in: Journal for immunotherapy of cancer (2022)
In heavily pretreated HER2-patients, immune consolidation with HER2 BATs after chemotherapy appears to increase the proportion of patients who were stable at 4 months and the median OS for both groups as well as increased adaptive and innate antitumor responses. Future studies combining HER2 BATs with checkpoint inhibitors or other immunomodulators may improve clinical outcomes.
Keyphrases
- phase ii
- clinical trial
- metastatic breast cancer
- open label
- end stage renal disease
- immune response
- newly diagnosed
- ejection fraction
- chronic kidney disease
- dna damage
- phase iii
- peritoneal dialysis
- double blind
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- locally advanced
- patient reported outcomes
- radiation therapy
- study protocol
- placebo controlled